Aflibercept with and without laser therapy in diabetic macular edema: a systematic review and meta-analysis
Abstract
Background: Diabetic macular edema (DME) causes visual impairment in diabetic patients. Aflibercept is a standard treatment of DME; however, the benefit of combining it with laser therapy remains uncertain.
Methods: A systematic review of randomized controlled trials (RCTs) comparing aflibercept alone with a combination of aflibercept plus laser therapy for management of DME was conducted. PubMed, Cochrane Library, and Embase were searched according to PRISMA guidelines. Primary outcomes were best corrected visual acuity (BCVA) and central macular thickness (CMT), while secondary outcome was treatment burden.
Results: Six RCTs involving 275 patients were included. At 12 months, combination therapy yielded a modest improvement in BCVA (mean difference [MD] = 0.18; 95% CI: -0.17 to 0.52; p = 0.32) and a minor reduction in CMT (MD = 0.13 μm; 95% CI: -0.13 to 0.39; p = 0.32). The number of aflibercept injections was slightly lower in the combination group (MD = -0.53 injections; 95% CI: -1.23 to 0.17; p = 0.14).
Conclusions: The adjunctive use of laser therapy with aflibercept in DME does not provide statistically significant improvement in visual or anatomical outcomes over aflibercept alone.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 275 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.